ADAM17 and COVID-19: Our primary MR analysis (Figure 1a, Supplementary Table S3) showed that a 1 SD increase in genetically determined circulating ADAM17 (extracellular domain) was associated with an increased risk of developing critical COVID-19 (odds ratio (OR) = 1.26, 95% CI: 1.03–1.55, inverse-variance weighted (IVW) method).